EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Cilostazol Contributes to Risk Reduction of Stroke Recurrence without Mediating a Reduction of Blood Pressure: Results from CSPS.com

Kaori Miwa, Masatoshi Koga, Katsuhiro Omae, Naruhiko Kamogawa, Shinichiro Uchiyama, Shoki Hayami, Masatoshi Shoji, Haruhiko Hoshino, Kazumi Kimura, Kazuo Minematsu, Takenori Yamaguchi, Kazunori Toyoda und 1 weitere

Journal of Atherosclerosis and Thrombosis · 2026

DOI: 10.5551/jat.65901 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2026. Verfasst von Kaori Miwa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center. Hauptthemen laut MEDLINE: Cilostazol, Blood Pressure, Stroke, Phosphodiesterase 3 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CilostazolBlood PressureStrokePhosphodiesterase 3 InhibitorsHumansMaleFemaleAgedRecurrenceMiddle AgedPlatelet Aggregation InhibitorsFollow-Up StudiesAspirinRisk FactorsClopidogrel

Stichwörter der Autor:innen

CilostazolIschemic strokeMediation analysisSystolic blood pressure

Substanzen

CilostazolPhosphodiesterase 3 InhibitorsPlatelet Aggregation InhibitorsAspirinClopidogrel

Autor:innen und Institutionen

  • Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
  • Department of Data Science, National Cerebral and Cardiovascular Center.
  • Clinical Research Center for Medicine, International University of Health and Welfare, Department of Neurology, Akasaka Sanno Medical Center.
  • Department of Neurology, Tokyo Saiseikai Central Hospital.
  • Department of Neurological Science, Graduate School of Medicine, Nippon Medical School.
  • Medical Corporation ISEIKAI.

Zitieren

APA

Miwa, K., Koga, M., Omae, K., Kamogawa, N., Uchiyama, S., Hayami, S., Shoji, M., Hoshino, H., Kimura, K., Minematsu, K., Yamaguchi, T., Toyoda, K., & CSPS.com Trial Investigators (2026). Cilostazol Contributes to Risk Reduction of Stroke Recurrence without Mediating a Reduction of Blood Pressure: Results from CSPS.com. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.65901

Vancouver

Miwa K, Koga M, Omae K, Kamogawa N, Uchiyama S, Hayami S, et al. Cilostazol Contributes to Risk Reduction of Stroke Recurrence without Mediating a Reduction of Blood Pressure: Results from CSPS.com. Journal of Atherosclerosis and Thrombosis. 2026. doi:10.5551/jat.65901

BibTeX
@article{Miwa2026,
  author = {Miwa, Kaori and Koga, Masatoshi and Omae, Katsuhiro and Kamogawa, Naruhiko and Uchiyama, Shinichiro and Hayami, Shoki and Shoji, Masatoshi and Hoshino, Haruhiko and Kimura, Kazumi and Minematsu, Kazuo and Yamaguchi, Takenori and Toyoda, Kazunori and CSPS.com Trial Investigators, CSPS.com Trial Investigators},
  title = {Cilostazol Contributes to Risk Reduction of Stroke Recurrence without Mediating a Reduction of Blood Pressure: Results from CSPS.com},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2026},
  doi = {10.5551/jat.65901}
}
Kostenlos starten →